In the combination treatments with PTC596 and trametinib strong cytotoxic effects were present in four MDS-AML and one B-ALL: MDS-AML 1, 3, 6 with adverse risk, the TP53 mutant MDS-AML2, and the B-ALL2. Here, TP53 is linked to myelodysplastic syndrome.